<DOC>
	<DOCNO>NCT02504190</DOCNO>
	<brief_summary>Lymphoma malignant blood disease sensitive chemotherapy . In case relapse first-line treatment , high-dose chemotherapy conditioning follow autologous hematopoietic stem cell transplantation ( auto-HSCT ) improve patient survival reduces risk relapse . Auto-HSCT may also indicate first line case aggressive lymphoma high risk relapse . BEAM ( Carmustine , Etoposide , Aracytine Melphalan ) frequently use high-dose conditioning regimen . Nevertheless , Carmustine longer available Europe . The investigator therefore chosen replace Carmustine Thiotepa use TEAM regimen new conditioning . Indeed , Thiotepa approve french national agency security drug ( ANSM ) use part auto-HSCT conditioning regimen . The result TEAM regimen term efficacy toxicity appear similar BEAM . However , study perform prospectively . Only small series case report report . If study confirm result retrospective study , condition TEAM could become new standard auto-HSCT treatment lymphoma . This study non-interventional , prospective 3 center . All include patient receive , accord standard practice drug label France , follow diagram : 1 . Conditioning : - Thiotepa 8 mg / kg J-6 - Etoposide 100 mg / m² / 12 h 4 day ( J-5 D-2 ) - Aracytine 200 mg / m² / 12 h 4 day ( J-5 D-2 ) - Melphalan 140 mg / m² day-1 2 . Transfusion graft : day D0 autologous peripheral stem cell transplant 3 . Care support : Patients treat accord usual procedure center participate study discretion investigator . 4 . Follow-up patient change study . The main objective study evaluate progression-free survival ( PFS ) lymphoma patient treat autologous stem cell condition TEAM Secondary objective : - To evaluate overall survival ; - To assess response treatment ; - evaluate incidence relapse ; - ass toxic transplant related mortality ; - study transplant-related morbidity ( infection , nutritional gastrointestinal toxicity , immune reconstitution ) .</brief_summary>
	<brief_title>Non-interventional Study TEAM Conditioning Patients With Lymphoma ( TEAM )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Patients age 18 65 year , lymphoma confirm biopsy first autologous haematopoietic stem cell transplantation TEAM conditioning VIH , HBV , and/or HCV seropositive Contraindication autologous stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>TEAM conditioning</keyword>
	<keyword>autologous stem cell transplantation</keyword>
</DOC>